Michael Hund joined EBRP as the CEO in 2017. Under his leadership EBRP has accelerated the EB landscape from 2 to over 40 clinical trials and via their award-winning venture philanthropy methodology helped fund the first FDA approved treatment for EB in 2023, the first ever topical gene therapy. EBRP’s innovative business model has garnered recognition from Harvard Business School, Yale University, MIT, Stanford, Rolling Stone, and Forbes. Previously Michael served as the Director of Development for the Multiple Myeloma Research Foundation and the $100 million Curing Cancer Now campaign, which led to more than 10 FDA approved treatments and the tripling of patient life expectancy. He also served for over a decade at Paul Newman’s Hole in the Wall Gang Fund, working on behalf of children and families battling life threatening illnesses. He has dedicated his career to transforming healthcare.
Michael received his Masters in Business Administration (MBA) from Yale University, CORe credential from Harvard Business School, and a degree in Philosophy from the University of Kansas. He is the recipient of the MIT Solve Horizon Innovation Award, iHeart Media’s CEOs You Should Know, the Milken Institute’s FasterCures Changemaker and LeadersLink mentor, Social Innovations Journal Leadership Award, Top 100 Magazine Innovators, and Authority Magazine’s Social Innovators. He lives in Connecticut with his wife Sarah and four daughters.
